Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Repligen nets $410mm through public sale of common shares and notes

Executive Summary

Repligen Corp. (biologics bioprocessing) netted $410mm through concurrent public offerings of common shares and senior notes. The company sold 1.6mm common (including the overallotment) at $87, and also issued $287.5mm aggregate amount (with the overallotment; $278.9mm net) of its 0.375% senior notes due 2024. The notes convert to common at a rate of 8.6749 common per $1k principal amount, or about $115.28 per share. (Repligen's stock averaged $85.47 at the time of the sales.)
Deal Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies